Loading...
Bienvenue sur la collection HAL du laboratoire de BECCOH
Quelques conseils pour une publication "idéHALe"
• Pensez à respecter la signature institutionnelle
Université Paris-Saclay, UVSQ, BECCOH, 92104, Boulogne-Billancourt, France..
• Participez à l'accès ouvert
N'attendez pas : dès que votre article est en ligne, déposez dans Hal sa version acceptée pour publication et indiquez un embargo de 6 mois.
La loi pour une république numérique vous autorise en effet à partager cette version 6 mois après publications, quelque-soit l'éditeur
Plus d'informations Archives Ouverte : quid de mes droits d'auteurs ?
• Vous souhaitez disposer d'une page web référençant toutes vos publications ?
Créez vous en 5 minutes un idHal et un CVHAL
N'hésitez pas à nous contacter pour toutes questions,
nous serions ravis d'échanger avec vous hal.bib@uvsq.fr
nous serions ravis d'échanger avec vous hal.bib@uvsq.fr
Dernières Publications en accès ouvert dans Hal
-
Paul Takam Kamga, Marie Mayenga, Louise Sebane, Adrien Costantini, Catherine Julie, et al.. Colony stimulating factor-1 (CSF-1) signalling is predictive of response to immune checkpoint inhibitors in advanced non-small cell lung cancer. Lung Cancer, 2024, 188, pp.107447. ⟨10.1016/j.lungcan.2023.107447⟩. ⟨hal-04517531⟩
-
Julie Lecuelle, Caroline Truntzer, Debora Basile, Luigi Laghi, Luana Greco, et al.. Machine learning evaluation of immune infiltrate through digital tumour score allows prediction of survival outcome in a pooled analysis of three international stage III colon cancer cohorts. EBioMedicine, 2024, 105, pp.105207. ⟨10.1016/j.ebiom.2024.105207⟩. ⟨hal-04626841⟩
-
Alexandra Kachaner, Raphaèle Seror, Fleur Cohen Aubart, Julien Henry, Thierry Lazure, et al.. Complete remission after a single bisphosphonate infusion in isolated bone Langerhans cell histiocytosis lesion: a case report and a narrative review of the literature. JBMR Plus, 2024, 8 (5), pp.ziae043. ⟨10.1093/jbmrpl/ziae043⟩. ⟨hal-04626829⟩
-
Robin Zagala, Nicolas Meyer, Philippe Saiag, Nora Kramkimel, Celeste Lebbe, et al.. Radiotherapy and prognostic factors in adnexal carcinomas: A retrospective study of 657 patients from the French CARADERM network. Journal of the European Academy of Dermatology and Venereology, In press, ⟨10.1111/jdv.20155⟩. ⟨hal-04626767⟩
-
Johanne Seguin, Mostafa El Hajjam, Josette Legagneux, Sarah Diakhaby, Nathalie Mignet, et al.. Radiofrequency Combined with Intratumoral Immunotherapy: Preclinical Results and Safety in Metastatic Colorectal Carcinoma. Pharmaceutics, 2024, 16 (3), pp.315. ⟨10.3390/pharmaceutics16030315⟩. ⟨hal-04626840⟩
-
Alexander Stratigos, Claus Garbe, Clio Dessinioti, Celeste Lebbe, Alexander van Akkooi, et al.. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment–Update 2023. European Journal of Cancer, 2023, 193, pp.113252. ⟨10.1016/j.ejca.2023.113252⟩. ⟨inserm-04209605⟩
-
Alexander Stratigos, Claus Garbe, Clio Dessinioti, Celeste Lebbe, Alexander van Akkooi, et al.. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention–Update 2023. European Journal of Cancer, 2023, 193, pp.113251. ⟨10.1016/j.ejca.2023.113251⟩. ⟨inserm-04210036⟩
Mots clés
Radiofrequency ablation
Beta-catenin
Body mass index
Chemoresistance
Advanced
Antineoplastic agents
BRAF V600E
Adverse events
Bisphosphonates
BRAFV600E
Anti-PD-1
2-chlorodeoxyadenosine
BRAF
Abscopal effect
Plasma
Allelic imbalance
Immune checkpoint inhibitor
Assisted reproductive techniques
ALK rearrangement
Cancer
Nivolumab
Advanced melanoma
BRAFV600-mutant melanoma
Adjuvant
ACTH
Staging
Chemotherapy
Anti-CTLA-4 anti-PD-1 elderly immune checkpoint inhibitors melanoma nonagenarian octogenarian
Colon cancer
Anti-Tumor pharmacology
Colorectal cancer
Trametinib
Sonic Hedgehog
Colorectal carcinoma
Prognostic
Mesenchymal stromal cells
Merkel cell carcinoma
Radiotherapy
ALK
Children
Anti-PD-1 antibody
Follow-up
Liver metastases
Anti-PD1
Circulating cell-free DNA
Adapted physical activity molecular diagnosis oligometastatic disease pancreatic adenocarcinoma KRAS mutation
Safety
Histiocytosis
Resistance
Adjuvant FOLFOX
Immunotherapy
Surgical excision
Wnt
Abscopal effect anti-PD-1 antibody melanoma nivolumab pembrolizumab radiotherapy
Lung adenocarcinoma
Invasive cutaneous squamous cell carcinoma
Biomarker
Acute generalized exanthematous pustulosis
Survival
Biomarkers
Locally advanced
Melanoma
Abdominal pain
Cutaneous squamous cell carcinoma
Prevention
BRAFV600E mutation
Oncology
Systemic therapy
Langerhans cell histiocytosis
Cancer bronchique non à petites cellules
Molecular targeted therapies
Prognosis
EGFR
Metastatic
Cemiplimab
Biliopancreatic diversion
ADN tumoral circulant
Diagnosis
Circulating tumor DNA
Osimertinib
Crizotinib
Anti-PD1 blockade
Androgen insensitivity
TNM classification
Metastatic cSCC
Non-small cell lung cancer
Treatment
Adjuvant therapy
AML
Anti-CTLA-4
Antibody-drug conjugate
Bariatric surgery
AZD9291
BRAF V600-mutation
Dabrafenib
Gastric bypass
Polyomavirus
Targeted therapy
Immunomodulation
Immunohistochemistry